Chronic kidney disease (CKD) has a high incidence and prevalence rate in whole world, and the most common causes of CKD include chronic glomerulonephritis (CGN), diabetic nephropathy and hypertensive renal sclerosis. Therefore, it is important to diagnose early, treat, and prevent CGN and CKD. The purpose of this study is to analyze the prescription patterns and frequencies of chinese herbal products (CHPs) for CGN by using a hospital-based database from the Chang Gung Memorial Hospital (CGMH), a large, tertiary hospital system in Taiwan and to evaluate the safety and possibly be efficacy of CHPs by blood test. The International Classification of Disease Ninth Revision (ICD-9) code 582 was used to identify patients with CGN. From 2000-2015, a total of 55,165 CHPs used by 4,865 CHP users for CGN were provided. Association rule mining was used to analyze the prevalent of CHP combination patterns in treating CGN. Jia-Wei-Xiao-Yao-San (JWXYS) and Gorgon (Euryale feroxSalisb.) were the most frequently prescribed herbal formula and single herb, respectively. The most frequently prescribed combination of CHPs was that of JWXYS with Bu-Yang-Huan-Wu-Tang (BYHWT) in CGMH. In statistical, there are significant changes of Creatinine、eGFR after treatment in 3-6-9 months in Stage 3b group.The more cumulative time and dosage of CHPs exposure were found to have more significant change of Creatinine and eGFR. To the best of our knowledge, this is the first pharmaco-epidemiological study to review CHP treatments for CGN. However, additional studies and clinical trials are needed to provide data on the safety and efficacy of these CHPs.